



Press release

SHL announces the closing of the transaction with Philips. Capital gain, net of taxes of around USD 35-40 million expected from the sale.

Tel Aviv/Zurich, 3 December 2007 – SHL Telemedicine Ltd. (SWX: SHLTN), a leading provider and developer of advanced personal telemedicine solutions, completed on 30 November 2007 the sale of Raytel Cardiac Services and other ancillary operations in the US to Royal Philips Electronics. The transaction with Philips had been approved and authorized by SHL's shareholders at a Special General Meeting held in Tel Aviv on 27 November 2007.

SHL received USD 110 million as upfront cash consideration and debt assumption. In addition, SHL will participate on a revenue sharing and royalty basis for up to 9 years in revenues of Raytel's current services and certain future services to be introduced in North America for which certain minimum payments will be made pending achievement of agreed upon milestones. SHL will also benefit from the sales of its proprietary telemedicine devices to Philips as well as from revenues emanating from Philips' access to SHL's future R&D.

SHL expects to record a capital gain, net of taxes of approximately USD 35-40 million from the sale of these operations and therefore expects a significant net profit for the year. Looking ahead, SHL's operations are to generate significant margins, profits and cash. Following the transaction SHL's cash position is extremely solid and will enable it to support its future strategic programs. SHL will provide a more detailed outlook and financial guidance early 2008.

Erez Alroy, Co-CEO of SHL, commented: "We are delighted that we were able to close the agreement with Philips so quickly. The transaction provides SHL with significant cash resources to increase the pace of its expansion in the German market as well as development of new markets and products."

About SHL TeleMedicine

SHL TeleMedicine Ltd. is a leading provider and developer of advanced personal telemedicine solutions to individuals and to the healthcare community. As a leading provider of remote health services in cardiology and in other medical areas, SHL maintains business operations in the US, Europe and Israel. SHL is listed on the SWX Swiss Exchange, symbol SHLTN. For more information please visit our web site on www.shl-telemedicine.com.

IR Agenda 2008:

26 March	FY results 2007
14 May	Annual General Meeting
20 May	Q1 results
26 August	Q2 results
18 November	Q3 results



For further information please contact:

- Erez Alroy, Co-CEO, Phone: +972 3561 22 12, ereza@shl-telemedicine.com
- Assistant: Pauline Shavit, Phone: +972 3561 22 12, pauline@shl-telemedicine.com
- Martin Meier-Pfister, The Investor Relations Firm AG, Phone: +41 43 244 81 40, shl@irfirm.biz

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.